Australia Termed No Longer Among Top Nations In Access To New Drugs
This article was originally published in PharmAsia News
Australia has dropped out of the world's top nations in providing early access to new drugs because its Pharmaceutical Benefits Scheme is lagging in subsidizing the drugs, the head of Medicines Australia said.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.